A human bone morphogenetic protein antagonist is down-regulated in renal cancer
about
Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior.Update on Wnt signaling in bone cell biology and bone disease.Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2Secreted and transmembrane wnt inhibitors and activators.SOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation.SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer.BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression.Serum sclerostin levels in renal cell carcinoma patients with bone metastasesCharacterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals.The complex roles of Wnt antagonists in RCC.Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.Diversity is in my veins: role of bone morphogenetic protein signaling during venous morphogenesis in zebrafish illustrates the heterogeneity within endothelial cellsHepcidin regulation in prostate and its disruption in prostate cancer.Agonists and Antagonists of TGF-β Family Ligands.In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion.A Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination.Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest.Transcriptional profiling of bovine intervertebral disc cells: implications for identification of normal and degenerate human intervertebral disc cell phenotypes.Bone morphogenetic protein signaling: implications in urology.Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.Contribution of the sclerostin domain-containing protein 1 (SOSTDC1) gene to normal variation of peak bone mineral density in Chinese women and men.Mechanistic basis for the chemopreventive effects of black raspberries at a late stage of rat esophageal carcinogenesis.Population-specific genetic modification of Huntington's disease in Venezuela.SOSTDC1 inhibits bone metastasis in non-small cell lung cancer and may serve as a clinical therapeutic targetE4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin
P2860
Q33597062-998FF497-A808-4D0B-8B0D-A84E14DA65C6Q34408171-C23F6B59-EFC1-41F1-B5B3-2D592EA10A74Q36035290-3ED5A4B6-6F72-4F5F-8FB4-AB5B0BA8C9DFQ36083303-06DB2C14-FFBD-469F-9A98-5591DF6E169CQ36544687-09F047B8-2E4E-4EC8-BE54-05C66B978C6DQ36626700-AE2EB7D1-D30E-434A-A8E4-3E44E1B96C0EQ36800327-AB7B3EB4-73B8-46C5-B1EF-0CC9DB4C2987Q36936190-5737C071-3997-49FD-A57D-B2D64FB976AEQ37234857-2B73463C-A5F4-4651-8D22-1DA8B3AE8389Q37282121-84D9EC55-B4C5-4D1A-82C4-10ACDF111677Q37371753-82055230-C8E8-432B-B09F-69E76FACEE69Q37949269-B910F415-D753-47E4-B61A-530FB44A4408Q38153283-067794F2-DB20-4CB3-AEF9-720460750978Q38233800-8907C662-6130-4311-B603-0B899A7312BBQ38889135-C69C3545-991E-4EBF-9F79-197606525CCEQ38896053-061B73AF-8EDC-4CCA-B410-CBCD97127F04Q39188239-4373C35A-5E6A-409A-A95E-0A7C283097BCQ39242337-222BFBA8-DD31-47BB-B405-D55EA417DEE4Q39935350-7844DE72-9AF1-4680-BF61-59F16D907CEDQ40726927-57117118-F90A-40B8-B523-95B7AEBF054BQ41783158-F7FD7CA6-81B5-4376-8714-25110B14F811Q49389245-0F7E1F8A-3ED2-46AB-84A5-006B58B5CA8CQ51518471-7B8C16D6-479F-46F9-AA1D-5AC981C990D6Q53288332-D3CF5558-1EE7-4FC6-8A96-262A34E7C39BQ55020670-2E1A69A3-5315-4455-8226-E8FAC7081BD4Q57478262-9F71BBB4-F782-4353-A06C-3D4E51B0AEB2Q58700293-96477E71-DA7C-48AB-8FA1-21741850DF5D
P2860
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
@ast
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
@en
type
label
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
@ast
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
@en
prefLabel
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
@ast
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
@en
P2093
P2860
P356
P1476
A human bone morphogenetic protein antagonist is down-regulated in renal cancer
@en
P2093
A Julian Garvin
Charles E Birse
Frank M Torti
Gregory A Hawkins
Julie C Brown
Kimberly Rose Blish
Mark C Willingham
Ralph B D'Agostino
Surekha R Krishnan
Suzy V Torti
P2860
P304
P356
10.1091/MBC.E07-05-0433
P577
2007-11-21T00:00:00Z